• CytoDyn closed a USD 16.5 million financing in an unregistered placement to fund development of leronlimab.
• Paulson Investment Company served as placement agent.
• Proceeds expected to fund operations into the second half of 2027.
• Net proceeds earmarked mainly for clinical trials, regulatory work, data analysis, manufacturing readiness, compliance, working capital.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytoDyn Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609010830PRIMZONEFULLFEED9819072) on September 01, 2026, and is solely responsible for the information contained therein.